Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
17 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Belgisch Centrum voor Farmacotherapeutische Informatie-Centre Belge d'Information Pharmacothérapeutique from Sint-Joost-ten-Node, company number BE0408045049, closed financial year 2025 with a result of € -100,318 after tax. For that financial year Belgisch Centrum voor Farmacotherapeutische Informatie-Centre Belge d'Information Pharmacothérapeutique recorded a gross margin of € 2.6 million and equity of € 1.6 million. Compared with financial year 2024, the result moved from € -40,384 to € -100,318. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 20, 2026.
€ 1.6 million
▼ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -100,318
▼ 148 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1.1 million
▼ 35% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
23.7
▲ 1.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.7 million
▲ 5% vs 2024
€ 113,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 13,336
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 120,976
▲ 218% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 413,969
▲ 8% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 3,101,685 | - | - | - | |
| Gross margin | € 2,436,723 | € 2,649,003 | € 2,496,798 | € 2,584,936 | ▲ 4% |
| Profit after taxes | € 151,217 | € 217,191 | € -40,384 | € -100,318 | ▼ € 59,935 |
| Equity | € 1,474,483 | € 1,691,674 | € 1,651,290 | € 1,550,972 | ▼ 6% |
| Total debts | € 896,756 | € 727,302 | € 670,314 | € 782,838 | ▲ 17% |
| Cash | € 1,821,461 | € 1,775,714 | € 1,656,990 | € 1,077,030 | ▼ 35% |
| Retained profit | € 1,474,483 | € 1,691,674 | € 1,651,290 | € 1,550,972 | ▼ 6% |
| Balance sheet total | € 2,371,238 | € 2,418,976 | € 2,321,604 | € 2,333,810 | ▲ 1% |
| Employees (FTE) | - | 22.1 | 22.6 | 23.7 | ▲ 1.1 |
Key figures of Belgisch Centrum voor Farmacotherapeutische Informatie-Centre Belge d'Information Pharmacothérapeutique, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Belgisch Centrum voor Farmacotherapeutische Informatie-Centre Belge d'Information Pharmacothérapeutique?
What happened at Belgisch Centrum voor Farmacotherapeutische Informatie-Centre Belge d'Information Pharmacothérapeutique in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Mathias Devreese stepped down as director. NBB
- Chris Ulens stepped down as director. NBB
- Hendrik De Rocker stepped down as director. NBB
- Alain Dupont stepped down as director. NBB
- Thierry Christiaens stepped down as director. NBB
- Stefan Degallaix stepped down as director. NBB
- Jean-Marie Maloteaux stepped down as director. NBB
- Philippe Jorens stepped down as director. NBB
In short
From € 151,217 profit in 2022 to € 100,318 loss in 2025.
Paid € 10,380 in corporate taxes since 2022.
Best year ever: 2023, with € 217,191 profit.
On average € 109,100 of value added per employee in 2025.
Management
Directors
According to the 2025 annual accounts
Mathias Devreese
Director
since 2025 · until 2027
Chris Ulens
Director
since 2025 · until 2027
Hendrik De Rocker
Director
Also active at: Association Pharmaceutique Belge-Algemene Pharmaceutische Bond, Ligue Cardiologique belge, S&H HOLDING
since 2025 · until 2027
Alain Dupont
Penningmeester
since 2025 · until 2027
Thierry Christiaens
Chairman of the board
since 2025 · until 2027
Stefan Degallaix
Director
since 2025 · until 2027
Jean-Marie Maloteaux
Vice-chairman of the board
since 2025 · until 2027
since 2025 · until 2027
Stefan Teughels
Director
Also active at: Vereniging van WijkGezondheidsCentra, Vlaams Instituut voor de Eerste Lijn, Dr.Stefan Teughels
since 2025 · until 2027
Pascal Gustin
Director
since 2025 · until 2027
André Herchuelz
Director
since 2025 · until 2027
Stéphanie Brillon
Director
since 2025 · until 2027
Vincent Seutin
Director
since 2025 · until 2027
Establishments
Establishment units
Physical locations of this company
Galileelaan 5 box /3
1210 Sint-Joost-ten-Node
Galileelaan 5
1210 Sint-Joost-ten-Node
Active since 1 October 2006
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 17 companies are registered at this address.
All companies at this address →Landesinstitut für Kranken- und Invalidenversicherung
Föderale öffentliche Dienst Volksgesundheit, Sicherheit der Nahrungsmittelkette und Umwelt
Vedeha
Tonibell
CODEP BANQUE D'EPARGNE - CODEP SPAARBANK - CODEP SAVINGS BANK - CODEP SPARBANK
+12 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0408.045.049
- VAT number
- BE 0408.045.049
- Registered office
- Galileelaan 5 bus /3, 1210 Sint-Joost-ten-Node
- Names & denominations
- Belgisch Centrum voor Farmacotherapeutische Informatie-Centre Belge d'Information Pharmacothérapeutique · BCFI - CBIP
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 30 December 1970
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Activiteiten van beroepsorganisaties
Beroepsorganisaties